GMS infectious diseases最新文献

{"title":"Trichosporon infection in chronic kidney disease patients from a tertiary care hospital - a case series or an outbreak? An unanswered question but a well-managed problem.","authors":"Heera Hassan, Alina Nair L, Varsha N S, Jyothi R, Aravind Reghukumar, Sathyabhama M C, Ragi R G, Neethu Kishor, Mithu M G, Syed Ali, Kiran Gopal, Manjusree S, Swathi V Koramboor, Anuja U","doi":"10.3205/id000090","DOIUrl":"10.3205/id000090","url":null,"abstract":"<p><p>While the majority of <i>Trichosporon</i> spp. isolated in clinical laboratories are typically associated with episodes of colonization or superficial infections, this fungal species has gained recognition as an opportunistic pathogen, leading to invasive infections worldwide. In this article, we present a case series of <i>Trichosporon</i> spp. identified through conventional methods, complemented by MALDI-TOF analysis from a reference institute for a single sample. The reported cases occurred within a confined time frame, and the construction of an epidemic curve suggested a common source with intermittent exposure. Despite the absence of identified breaches in infection prevention and control (IPC) in units with common exposure, this case series underscores the significance of considering Trichosporonosis in the differential diagnoses for post-transplant and chronic kidney disease patients, particularly those undergoing hemodialysis or utilizing Foley's catheter. Notably, research gaps were identified, emphasizing the need for further exploration of factors such as the role of magnesium and prolonged antibiotic usage in the development of invasive <i>Trichosporon</i> infections and newer treatment modalities against biofilm producing yeast like fungi.</p>","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"12 ","pages":"Doc05"},"PeriodicalIF":0.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11636554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fusarium spp.: infections and intoxications.","authors":"Herbert Hof, Jens Schrecker","doi":"10.3205/id000089","DOIUrl":"10.3205/id000089","url":null,"abstract":"<p><p>The genus <i>Fusarium</i>, member of the <i>Hypocreaceae</i> family, comprises over 500 spp. with an ever-evolving taxonomy. These fungi, some highly pathogenic, primarily affect various plants, including major crops like maize, rice, cereals, and potatoes, leading to significant agricultural losses and contributing to human undernutrition in certain regions. Additionally, <i>Fusarium</i> spp. produce harmful mycotoxins like trichothecenes, fumonisins, zearalenones, etc., posing health risks to animals and humans. These toxins generally transferred to food items can cause diverse issues, including organ failure, cancer, and hormonal disturbances, with effects sometimes appearing years after exposure. The fungi's vast genetic repertoire enables them to produce a range of virulence factors, leading to infections in both animals and humans, particularly in immunocompromised individuals. <i>Fusarium</i> spp. can cause systemic infections and local infections like keratitis. Due to limited antifungal effectiveness and biofilm formation, these infections are often challenging to treat with poor outcomes.</p>","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"12 ","pages":"Doc04"},"PeriodicalIF":0.0,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11463004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A complex case of bacterial pericarditis caused by a new pathogenic agent.","authors":"Joana Lima Lopes, Daniel Candeias Faria, Bárbara Flor-de-Lima, Márcio Madeira, Sara Ranchordas, José Pedro Neves, João Baltazar Ferreira","doi":"10.3205/id000088","DOIUrl":"10.3205/id000088","url":null,"abstract":"<p><p><i>Dermabacter hominis</i> is a gram-positive facultative anaerobic agent. It is a human skin colonizer that can be responsible for opportunistic infections in immunocompromised patients. To date, the infections caused by this agent are related to bone, joint, eye, peritoneal dialysis catheters, abscesses or infected vascular grafts. Overall, it has a favorable outcome with good response to vancomycin, teicoplanin or linezolide, and so it has not been considered a concerning pathogenic agent. We present the first case in scientific literature with isolation of <i>D. hominis</i> in pericardial fluid in the setting of infectious bacterial pericarditis, with an aggressive course and poor evolution.</p>","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"12 ","pages":"Doc03"},"PeriodicalIF":0.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11463003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The interpretation of COVID-19 in cause-of-death statistics: a matter of causality.","authors":"Peter P M Harteloh","doi":"10.3205/id000087","DOIUrl":"10.3205/id000087","url":null,"abstract":"<p><strong>Background: </strong>Mortality is an important indicator for estimating the impact of the COVID-19 pandemic. However, different registrations provide different figures and the question is how to interpret the number of COVID-19 deaths reported.</p><p><strong>Objective: </strong>To study the role of COVID-19 in dying in order to explain the representation of COVID-19 in cause-of-death statistics.</p><p><strong>Methods: </strong>Analysis of all death certificates mentioning COVID-19 in the Dutch cause-of-death registry during the pandemic (n=51,181). The role of COVID-19 as cause of death was studied by the way it was reported on death certificates. A calculation of odds ratios was performed for studying associations between COVID-19 and other reported causes of death.</p><p><strong>Results: </strong>In 24% of the cases COVID-19 was the only cause of death mentioned on a death certificate. In 76% of the cases, one or more other diseases played a role in dying. Three patterns emerged: COVID-19 associated with 1. neurodegenerative disorders, 2. chronic respiratory disorders, and 3. metabolic disorders. Of all death certificates mentioning the diseases, COVID-19 was the start of the causal chain leading to death in 45.2% of the cases, while COVID-19 was selected for cause-of-death statistics by special World Health Organization WHO instructions in 93.9% of the cases.</p><p><strong>Conclusions: </strong>Cause-of-death statistics overestimate the role of COVID-19 as underlying cause of death. In a majority of the deceased cases, there is an association of COVID-19 with other diseases not captured by cause-of-death statistics reporting (only) one cause of death per deceased. A multi-causal approach is needed to evaluate the pandemic and inform health policy.</p>","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"12 ","pages":"Doc02"},"PeriodicalIF":0.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11463002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic strategies for uncomplicated cystitis in women.","authors":"Kurt G Naber, Jakhongir F Alidjanov, Reinhard Fünfstück, Walter L Strohmaier, Jennifer Kranz, Tommaso Cai, Adrian Pilatz, Florian M Wagenlehner","doi":"10.3205/id000086","DOIUrl":"10.3205/id000086","url":null,"abstract":"<p><p>Uncomplicated cystitis is affecting many women of all ages and has a great impact on the quality of life, especially in women suffering from recurrent, uncomplicated cystitis. By far the most frequent uropathogen, <i>E. coli</i>, may have acquired increasing resistance against a variety of oral antibiotics, which may differ between countries and regions. Therefore, local resistance data are important to be considered. On the other hand, non-antibiotic therapy has also become an option which should be discussed and offered to the patient. In patients suffering from recurrent uncomplicated cystitis, individual risk factors and possible behavioral changes should first be taken into account. Non-antimicrobial prophylactic strategies shown to be successful in well-designed clinical studies are the next options. Long term antibiotic prophylaxis, however, should only be considered as a last option. For some of those patients self-diagnosis and self-treatment may be suitable, e.g. by using a recognized questionnaire.</p>","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"12 ","pages":"Doc01"},"PeriodicalIF":0.0,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11099625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141066181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Q fever, a rare cause of secondary hemophagocytic lymphohistiocytosis.","authors":"Juan Francisco Nieves Salceda, Pablo Lozano Cuesta, Sara Hermoso de Mendoza Aristegui, Jonathan Fernández-Suárez, Claudia Madrid Carbajal, Marta María García Clemente","doi":"10.3205/id000085","DOIUrl":"https://doi.org/10.3205/id000085","url":null,"abstract":"<p><p>Hemophagocytic lymphohistiocytosis (HLH) is a rare syndrome in which <i>Coxiella burnetii</i> is a very infrequent etiology. We present the case of a 62-year-old male with progressive pulmonary infiltrates, fever, hepatitis, and bicytopenia despite broad spectrum antibiotics. A thorough clinical evaluation led to a high suspicion of <i>Coxiella burnetii</i> infection, subsequently confirmed through a positive serum polymerase chain reaction (PCR) analysis. HLH diagnosis was established based on the fulfillment of 5/8 diagnostic criteria, obviating the need for a bone marrow biopsy. Targeted antibiotic treatment and dexamethasone led to full recovery within two weeks, eliminating the need for stronger immunosuppressive therapy.</p>","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"11 ","pages":"Doc05"},"PeriodicalIF":0.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10726720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138815603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AWaRe-based culture reporting format: a novel tool for antimicrobial stewardship.","authors":"Heera Hassan, Jyothi R, Sreenadh H, Manjusree S, Aravind Reghukumar","doi":"10.3205/id000084","DOIUrl":"https://doi.org/10.3205/id000084","url":null,"abstract":"","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"11 ","pages":"Doc04"},"PeriodicalIF":0.0,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10726719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138815602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 treatment strategies with drugs centrally procured by the German Federal Ministry of Health in a representative tertiary care hospital: a temporal analysis.","authors":"Kathrin Marx, Sven Kalbitz, Nils Kellner, Maike Fedders, Christoph Lübbert","doi":"10.3205/id000083","DOIUrl":"10.3205/id000083","url":null,"abstract":"<p><strong>Introduction: </strong>To ensure the fastest and earliest possible treatment, the German Federal Ministry of Health (BMG) initiated central procurement and nationwide distribution of new drugs against COVID-19. A single centre was used for a retrospective temporal analysis of this procedure.</p><p><strong>Methods: </strong>A descriptive analysis of hospitalization and treatment of COVID-19 patients with drugs centrally procured by the BMG at St. Georg Hospital, Leipzig, Germany, for the period from 1 March 2020 to 28 February 2023 was employed considering the approval status, evolving guidelines and recommendations of medical societies.</p><p><strong>Results: </strong>In total, 3,412 patients ≥18 years (54.9% men) with PCR-confirmed SARS-CoV-2 infection were admitted. The mean age was 64 years during the reporting period and 66.1/70.6 years during the first and second COVID-19 waves, respectively. 964 patients (28.2%) received COVID-19 therapy with drugs procured centrally by the BMG. Remdesivir was the most commonly used (63%). SARS-CoV-2 neutralizing monoclonal antibodies represented 23% of the therapies. Peroral antivirals (nirmatrelvir/ritonavir and molnupiravir) were used in 14% of COVID-19 patients, with molnupiravir being insignificant (five prescriptions).</p><p><strong>Conclusions: </strong>Specific therapeutic approaches were mainly based on antiviral therapy in the early phase of COVID-19 to prevent severe disease progression in vulnerable patient groups. Most drugs had not been approved at the time of central procurement; therefore, prescriptions were given on a case-by-case basis after careful risk-benefit assessments. All available neutralizing monoclonal SARS-CoV-2 antibodies lost efficacy during the pandemic due to different circulating immune escape variants. Remdesivir and nirmatrelvir/ritonavir remained effective therapies in the early phase of COVID-19.</p>","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"11 ","pages":"Doc03"},"PeriodicalIF":0.0,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41223256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamics of immunity over time: decline of anti-SARS-CoV-2 IgG antibodies and T-cell responses after mRNA vaccination in residents and health care workers in nursing homes and homes with assisted living support.","authors":"Julia Schiffner,&nbsp;Nora Eisemann,&nbsp;Hannah Baltus,&nbsp;Sina Jensen,&nbsp;Katharina Wunderlich,&nbsp;Stefan Schuesseler,&nbsp;Charlotte Eicker,&nbsp;Bianca Teegen,&nbsp;Doreen Boniakowsky,&nbsp;Werner Solbach,&nbsp;Alexander Mischnik","doi":"10.3205/id000082","DOIUrl":"10.3205/id000082","url":null,"abstract":"<p><strong>Background: </strong>In the present study, we investigated the dynamics of immunity over time by measuring anti SARS-CoV-2 IgG antibodies and SARS-CoV-2 specific T-cell responses (interferon-gamma release assay) after two doses of vaccines in residents and health care workers (HCW). Mostly, 224 (98%) residents and 244 (89%) HCW received two doses of mRNA vaccine (BNT162b2, Pfizer-BioNTech); the rest of the participants received heterologous vaccinations with mRNA and vector vaccines. The study was conducted at the time when the Delta variant of SARS-CoV-2 prevailed.</p><p><strong>Methods: </strong>We analyzed blood samples of 228 residents (median age 83.8 years) and of 273 HCW (median age 49.7 years) from five nursing homes and one home for the elderly with assisted living support at one specific time point. Participants received two vaccinations. The blood samples were analyzed for SARS-CoV-2 specific IgG antibody and T-cell responses.</p><p><strong>Results: </strong>The initial immune responses in the younger participants were about 30% higher than in the older age group. Over time the estimated mean of the parameters (estimated from the study sample for the total population) decreased in all groups within the maximum observation period of 232 days. Comorbidities such as coronary heart disease or diabetes mellitus reduced the initial immune responses regardless of age. With regard to measured IgG antibody levels, absolute values decreased over time, whereas the interferon-gamma response remained at a constant level between day 120 and 180 and seemed to be less dependent on the time elapsed after vaccination.</p><p><strong>Conclusions: </strong>Based on our data, it does not seem possible to determine a reliable threshold of robust immunity, but we suggest that high titres of neutralizing capacity and interferon-gamma response might be an indicator of protection against severe COVID-19 courses.</p>","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"11 ","pages":"Doc02"},"PeriodicalIF":0.0,"publicationDate":"2023-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41223257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Treponema-specific immunoglobulin G (IgG) index with Treponema pallidum particle agglutination (TPPA) index for detection of intrathecal Treponema-specific antibody synthesis for serological diagnosis of neurosyphilis.","authors":"Nele Wellinghausen,&nbsp;Andrea Götz,&nbsp;Teresa Esthela Rangel Vivar","doi":"10.3205/id000081","DOIUrl":"10.3205/id000081","url":null,"abstract":"<p><p>The determination of <i>Treponema</i>-specific intrathecal immunoglobulin synthesis with the <i>Treponema</i> <i>pallidum</i> particle agglutination (TPPA) index is a well-established method recommended in German guidelines for the diagnosis of neurosyphilis. However, the TPPA test is no longer available. The aim of this study was to evaluate whether the determination of a <i>Treponema</i>-specific immunoglobulin G (IgG) index can substitute the TPPA index. Serum and cerebrospinal fluid (CSF) samples from patients with confirmed (n=6) and probable (n=3) neurosyphilis as well as patients with adequately treated syphilis without neurosyphilis (n=4) were investigated. In addition to index calculation further CSF parameters were determined. The results of the <i>Treponema</i> IgG and the TPPA index were consistent in all patients with confirmed neurosyphilis and non-neurosyphilis patients. In two patients with probable neurosyphilis the IgG index appeared more plausible than the TPPA index when taking into account all available laboratory and clinical data of the patients. In conclusion, the determination of <i>Treponema</i>-specific intrathecal immunoglobulin synthesis with the IgG index appears to be a suitable alternative to the TPPA index.</p>","PeriodicalId":91688,"journal":{"name":"GMS infectious diseases","volume":"11 ","pages":"Doc01"},"PeriodicalIF":0.0,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585769/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49694966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}